avelumab + palbociclib

Avelumab + palbociclib is an investigational combination therapy consisting of two distinct agents used together for the treatment of certain cancers. Avelumab is a fully human monoclonal antibody that targets programmed death-ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. Palbociclib is a selective small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which blocks cell cycle progression in cancer cells, leading to growth arrest. This combination aims to leverage both immunomodulatory and cell cycle inhibitory mechanisms, with ongoing clinical trials primarily in breast cancer (especially androgen receptor-positive triple negative breast cancer) and other solid tumors[3][4][5][7].